PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 27, 2026JNCI Cancer Spectrum0 citationsOpen Access

Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer

View Full Paper
YMYehoda M. MarteiKCKan ChenMOModesty Obasohan

Key Points

  • The study aims to investigate the trends in utilization of first-line targeted therapies for metastatic breast cancer and the associated racial disparities.
  • Examined utilization trends of CDK4/6 inhibitors and pertuzumab in metastatic breast cancer.
  • Identified racial disparities between non-Hispanic Black (NHB) and non-Hispanic White (NHW) patients.
  • Performed data analysis on therapy utilization rates over time.
  • NHB patients were less likely to receive CDK4/6 inhibitors compared to NHW patients.
  • About 50% of eligible patients did not receive pertuzumab.
  • Further research is needed to understand factors leading to the underutilization of these therapies among different racial groups.

Abstract

Utilization of targeted therapies increased over time, however NHB patients were less likely to receive CDK4/6i compared to NHW. Approximately half of eligible patients did not receive pertuzumab. Further research is needed to understand mediators and design interventions to address underutilization of these therapies and those contributing to racial disparities in CDK4/6i utilization.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Martei et al. (2026) studied this question.

synapsesocial.com/papers/69eefdb5fede9185760d47b0https://doi.org/10.1093/jncics/pkag043
Ask AI
Helpful
Bookmark
Share
View Full Paper